ICT is in the business of producing biological solutions of allo-stem cell transplant material and is engaged in continuing research and development regarding the production and use of stem cells. It is the owner of a unique process for the preparation, production and freezing of the biological solutions of human stem cells and currently holds 26 patents that have been derived from the intellectual property of its scientists used to develop the stem cell production and cryo-freezing processes. The patents and technology are a part of the license to Stem Cell Therapy International.

Scientists at ICT began researching stem cell capabilities in 1972. Since 1981, ICT's research and production of biological preparations from animal and human cells, have been in the framework of the scientific programs under the aegis of the National Academy of Sciences, Medical Academy of Sciences, Ministry of Public Health and the Coordination Center of organ, tissue and cell transplantation of the Ministry of Public Health. In the Territory of Ukraine, the application of embryonic preparations have been monitored and allowed by the Ministry of Public Health since 1991.

Under the terms of the agreement, SCTI has been granted the global rights to use the IP contained in the patents, the stem cell products and the process itself, to establish clinics for the treatment of patients, set up cryo-storage facilities and the administration of the stem cell products to its customers including clinics, universities, institutes and private research facilities for study and clinical trials. Numerous patients have already been treated and now new patients can receive stem cell transplantation therapy through SCTI at the ICT Clinic facility in Kiev.

SCTI Chairman and CEO, Calvin Cao, says, "We are extremely pleased and excited about the signing of the exclusive License Agreement with ICT. It gives SCTI a reputable and reliable source of new allo-stem cell lines and other technologies, which will be used for the treatment of patients globally and for further study and research purposes here in the United States. We plan to use SCTI's management expertise and resources for the administration, marketing, advertising and distribution of the ICT stem cell products."

Stem cell transplantation therapy is a field of medicine, which uses techniques and technologies that rely on replacing diseased, damaged or dysfunctional cells with healthy, functioning ones. This therapy is similar to the process of organ transplantation, only the treatment consists of the transplantation of stem cells into the body rather than entire organs, thus eliminating any chance of rejection or the need for immunosuppression drugs. These new techniques are being applied to finding a cure for a wide range of human disorders, including neurological diseases such as Alzheimer's, Parkinson's Disease, ALS (Lou Gehrig's disease), leukemia, muscular dystrophy, multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke, heart disease, liver and retinal disease, diabetes as well as certain types of cancer and the side effects of chemotherapy.

With the enactment of Proposition 71 in California in November 2004, a fund of $3 billion was created to fund stem cell research. Since then three other states New Jersey, Connecticut and Illinois, have allocated funds for stem cell research. Among the leading public companies in the U.S. in the field of stem cell technology are A.C.T. Holdings, Inc.; ViaCell; Geron; StemCells, Inc., and Aastrom Biosciences Inc. For additional information, please visit our website at www.scticorp.com.

About Stem Cell Therapy International Corp.

Stem Cell Therapy International Corp. (SCTI) is in the field of regenerative medicine. SCTI provides new stem cell solutions, which are being used in the treatment of patients suffering from degenerative disorders of the human body. SCTI operates in conjunction with advanced medical facilities devoted to the treatment of human physical disorders with stem cell transplantation therapy. The company intends to continue to establish relationships with highly specialized, professional medical treatment centers outside of the United States that will treat patients with the stem cell transplantation therapy. In addition, SCTI intends to provide biological solutions containing new stem cell products in the United States to universities, institutes and privately funded laboratory facilities for research purposes and clinical trials.

Forward Looking Statements

This report includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development acceptance, and the impact of competitive services and pricing and general economic risks and uncertainties.

Source Stem Cell Therapy International, Inc.